Please use this identifier to cite or link to this item: https://essuir.sumdu.edu.ua/handle/123456789/87897
Or use following links to share this resource in social networks: Recommend this item
Title Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
Authors Shah, M.A.
Udrea, A.A.
Bondarenko, I.
Mansoor, W.
Sánchez, R.G.
Sarosiek, T.
Bozzarelli, S.
Schenker, M.
Gomez-Martin, C.
Morgan, C.
Özgüroğlu, M.
Pikiel, J.
Kalofonos, H.P.
Wojcik, E.
Buchler, T.
Swinson, D.
Cicin, I.
Joseph, M.
Vynnychenko, Ihor Oleksandrovych  
Luft, A.V.
Enzinger, P.C.
Salek, T.
Papandreou, C.
Tournigand, C.
Maiello, E.
Wei, R.
Ferry, D.
Gao, L.
Oliveira, J.M.
Ajani, J.A.
ORCID http://orcid.org/0000-0002-2339-6509
Keywords angiogenesis
gastric adenocarcinoma
ramucirumab
vascular endothelial growth factor receptor
Type Article
Date of Issue 2022
URI https://essuir.sumdu.edu.ua/handle/123456789/87897
Publisher MDPI
License Creative Commons Attribution 4.0 International License
Citation Shah, M.A.; Udrea, A.A.; Bondarenko, I.; Mansoor, W.; Sánchez, R.G.; Sarosiek, T.; Bozzarelli, S.; Schenker, M.; Gomez-Martin, C.; Morgan, C.; Özgüroğlu, M.; Pikiel, J.; Kalofonos, H.P.; Wojcik, E.; Buchler, T.; Swinson, D.; Cicin, I.; Joseph, M.; Vynnychenko, I.; Luft, A.V.; Enzinger, P.C.; Salek, T.; Papandreou, C.; Tournigand, C.; Maiello, E.; Wei, R.; Ferry, D.; Gao, L.; Oliveira, J.M.; Ajani, J.A. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers 2022, 14, 1168. https://doi.org/10.3390/cancers14051168
Abstract Studies JVDB and JVCZ examined alternative ramucirumab dosing regimens as monotherapy or combined with paclitaxel, respectively, in patients with advanced/metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. For JVDB, randomized patients (N = 164) received ramucirumab monotherapy at four doses: 8 mg/kg every 2 weeks (Q2W) (registered dose), 12 mg/kg Q2W, 6 mg/kg weekly (QW), or 8 mg/kg on days 1 and 8 (D1D8) every 3 weeks (Q3W). The primary objectives were the safety and pharmacokinetics of ramucirumab monotherapy. For JVCZ, randomized patients (N = 245) received paclitaxel (80 mg/m2-D1D8D15) plus ramucirumab (8 mg/kg- or 12 mg/kg-Q2W). The primary objective was progression-free survival (PFS) of 12 mg/kg-Q2W arm versus placebo from RAINBOW using meta-analysis. Relative to the registered dose, exploratory dosing regimens (EDRs) led to higher ramucirumab serum concentrations in both studies. EDR safety profiles were consistent with previous studies. In JVDB, serious adverse events occurred more frequently in the 8 mg/kg-D1D8-Q3W arm versus the registered dose; 6 mg/kg-QW EDR had a higher incidence of bleeding/hemorrhage. In JVCZ, PFS was improved with the 12 mg/kg plus paclitaxel combination versus placebo in RAINBOW; however, no significant PFS improvement was observed between the 12 mg/kg and 8 mg/kg arms. The lack of a dose/exposure-response relationship in these studies supports the standard dose of ramucirumab 8 mg/kg-Q2W as monotherapy or in combination with paclitaxel as second-line treatment for advanced/metastatic gastric/GEJ adenocarcinoma.
Appears in Collections: Наукові видання (НН МІ)

Views

Australia Australia
1
Belgium Belgium
63987
Germany Germany
1
Ireland Ireland
168
Singapore Singapore
1
Ukraine Ukraine
6657
United Kingdom United Kingdom
851
United States United States
63985
Unknown Country Unknown Country
6653

Downloads

Belgium Belgium
1
Germany Germany
1
Ireland Ireland
169
Ukraine Ukraine
6658
United States United States
49650

Files

File Size Format Downloads
Shah_et_al_angiogenesis_2022.pdf 1.75 MB Adobe PDF 56479

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.